Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

About Orabio

Founded in 2005 Ora Bio Ltd, a biopharmaceutical company, is engaged in the repositioning of existing drugs for second-use applications. nnThe Company is developing its two products, the ORA101 and ORA102, as drugs for non-small cell lung cancer (NSCLC) and age-related macular degeneration (AMD) respectively. Both the company's products are currently in Phase II clinical trials.n

Orabio Headquarter Location

P.O.B. 2252

16000,

Israel

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Orabio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Orabio is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

E

Eye Health

711 items

C

Cancer

4,844 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.